Summary

Creates a new FTC enforcement rule that treats certain product-switching tactics by drug and biologic manufacturers as unfair methods of competition. It defines “hard” and “soft” switches, lists narrow exceptions and justifications manufacturers may use, and gives the Federal Trade Commission authority and procedures to challenge such switches in court. The measure is aimed at preserving competition from generics and biosimilars by limiting tactics that delay or block substitution. It sets how and when the rule applies and establishes judicial-review and enforcement pathways for the FTC to pursue remedies.

Key Points

• Creates an FTC-enforceable prohibition on certain product-switching tactics by drug and biologic manufacturers.
• Defines "hard switches" (withdraw and replace) and "soft switches" (introduce new version while undermining the old) as covered conduct when they impede substitution.
• Includes limited exceptions and possible justifications for product changes, such as legitimate safety or regulatory reasons.
• Gives the FTC authority and procedures to bring enforcement actions and specifies judicial-review mechanisms.
• Aims to protect generic and biosimilar competition and help maintain lower-cost alternatives for patients and payers.
• Raises compliance and litigation risk for manufacturers that use reformulations, withdrawals, or marketing strategies to extend market exclusivity.
• Does not broadly rewrite patent or FDA law; it creates an antitrust/competition enforcement pathway focused on market-impacting conduct.
• Applies prospectively according to the provision’s timing rules; the text sets when the new authority governs manufacturer conduct.

Categories & Tags